Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna, COVID-19
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal. Pfizer and its German partner BioNTech sued Moderna in London in September 2022,
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in the fall of 2024." The organization recommends a six-month interval between COVID vaccines, "with a minimum of three months from the last dose."
Moderna's updated COVID-19 vaccine approved in Canada
Health Canada has authorized Moderna's updated COVID-19 vaccine to roll out in fall immunization campaigns. The new Spikevax formula targets the KP.2 subvariant, one of the latest offshoots of the Omicron variant of the virus that causes COVID-19.
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine.Moderna's Spikevax KP.2 targets the KP.2 variant of the virus.The U.S. Food and Drug Administration has also approved the shot,
STAT
1d
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Hosted on MSN
1d
Moderna blamed after children offered £1,500 to take part in Covid-19 trial
Under the EU Clinical Trials Regulation, financial incentives are not allowed for participants under 16 to prevent undue ...
1d
Moderna enters green after six straight sessions in red
Moderna ( NASDAQ: MRNA) shares snapped six straight sessions of losses, as the stock closed 0.46% higher at $63.93 on ...
14d
on MSN
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
1d
Moderna Inc. stock rises Thursday, still underperforms market
Shares of Moderna Inc. MRNA inched 0.46% higher to $63.93 Thursday, on what proved to be an all-around positive trading ...
12d
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
7d
Down 13% in 1 Day, Is Moderna Stock in Trouble?
Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...
15d
on MSN
Moderna lays out plan to slice research and development spending
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...
3d
Moderna Inc. stock underperforms Tuesday when compared to competitors
Shares of Moderna Inc. MRNA dropped 0.31% to $63.94 Tuesday, on what proved to be an all-around favorable trading session for ...
12d
Moderna: Cutting Costs At Just The Worst Time
Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...
2d
As GSK discontinues HSV vaccine, opportunities remain for Moderna and BioNTech
GSK's decision not to advance the vaccine into Phase III trials ends its ambition to bring the first HSV vaccine to market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback